Joshua Pinto

Insider Reports History

Location
Watertown, MA
Signature
/s/ Michael Milligan, as Attorney-in-Fact for Joshua Pinto
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Joshua Pinto:

Company Role Class Num Shares Value Price $ Report Date Ownership
Neumora Therapeutics, Inc. President Common Stock 152,167 $117,168 $0.7700 21 May 2025 Indirect
Neumora Therapeutics, Inc. President Common Stock 63,750 $49,087 $0.7700 21 May 2025 Direct
Metsera, Inc. Director Common Stock 0 $0 $52.33 13 Nov 2025 Direct
Neumora Therapeutics, Inc. President Stock Option (Right to Buy) 1,200,000 08 Jan 2026 Direct
Metsera, Inc. Director Restricted Stock Unit 2,688 13 Nov 2025 Direct
Metsera, Inc. Director Stock Option (right to buy) 0 13 Nov 2025 By LLC
Metsera, Inc. Director Stock Option (right to buy) 0 13 Nov 2025 Direct

Insider Reports Filed by Joshua Pinto

Symbol Company Period Transactions Value $ Form Type Role Filing Time
NMRA Neumora Therapeutics, Inc. 08 Jan 2026 1 $0 4 President 09 Jan 2026, 16:18
MTSR Metsera, Inc. 13 Nov 2025 4 $0 4 Director 13 Nov 2025, 21:00
NMRA Neumora Therapeutics, Inc. 28 May 2025 14 $0 4 President 30 May 2025, 18:25
NMRA Neumora Therapeutics, Inc. 21 May 2025 2 $0 4 President 23 May 2025, 16:42
MTSR Metsera, Inc. 20 May 2025 3 $0 4 Director 22 May 2025, 19:42
NMRA Neumora Therapeutics, Inc. 18 Feb 2025 1 -$13,477 4 President 20 Feb 2025, 17:11
NMRA Neumora Therapeutics, Inc. 13 Feb 2025 13 $0 4 President 18 Feb 2025, 16:30
MTSR Metsera, Inc. 30 Jan 2025 0 $0 3 Director 30 Jan 2025, 21:28
NMRA Neumora Therapeutics, Inc. 27 Aug 2024 1 -$178,806 4 Chief Financial Officer 27 Aug 2024, 17:58
NMRA Neumora Therapeutics, Inc. 22 Aug 2024 3 -$984,061 4 Chief Financial Officer 26 Aug 2024, 18:17
NMRA Neumora Therapeutics, Inc. 17 Apr 2024 1 $0 4 Chief Financial Officer 28 Jun 2024, 21:00
NMRA Neumora Therapeutics, Inc. 14 Feb 2024 2 $0 4 Chief Financial Officer 16 Feb 2024, 16:21
NMRA Neumora Therapeutics, Inc. 14 Sep 2023 0 $0 3 Chief Financial Officer 14 Sep 2023, 18:52